Heart Failure

- Critically ill subjects
- Male (older than 18 years ) and female (older than 55 years)
- Admitted to hospital with decompensated chronic CHF and clinical indication for parenteral pharmacotherapy with invasive hemodynamic monitoring and a pulmonary capillary wedge pressure of ≥18 mmHg
- Postmenopausal female subjects or women without child bearing potential based on surgical treatment like bilateral tubal ligation, bilateral ovariectomy, or hysterectomy

- Women with childbearing potential;
- Heart failure NYHA Class I and II
- Acute heart failure (blood pressure <100 mmHg systolic or <60 mmHg diastolic, need for acute cardiological intervention or surgery, cardiogenic shock, primary need for catecholamines, need for invasive mechanical ventilation)
- Unstable subjects
- Subjects with acute coronary syndrome;
- Renal insufficiency with serum creatinine ≥2 mg/dL (177 µmol/L);
- Participation in another clinical trial during the preceding 3 months;
- Resting heart rate in the awake subject below 45 BPM or above 120 BPM;
- Relevant pathological changes in the ECG such as a second or third-degree AV block
- Medical disorders, condition or history that would impair the subject’s ability to participate or complete this study including the history of relevant diseases of vital organs, of the central nervous system; and febrile illness within 1 week before the start of the study
- Subjects with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies or with hypersensitivity to the investigational drug, the control agent and/ or to inactive constituents